HR Execs on the Move

Regulatory and Clinical Research Institute

www.rcri-inc.com

 
Regulatory & Clinical Research Institute, Inc. is a Minneapolis, MN-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.rcri-inc.com
  • 5353 Wayzata Blvd Ste 505
    Minneapolis, MN USA 55416
  • Phone: 952.746.8080

Executives

Name Title Contact Details

Similar Companies

Total Care Rx

Total Care RX serves as an extension of the patient’s medical team to monitor medication compliance, provide education and offer other value-added services not offered by retail pharmacies.

Advanced Accelerator Applications

Advanced Accelerator Applications is a pharmaceutical group specialized in the field of nuclear medicine.

Covidien

Covidien Ltd. (Covidien) is engaged in the development, manufacture and sale of healthcare products for use in clinical and home settings. Covidien is part of the local fabric of the communities in which we operate around the world. Our success is made possible through the dedication of our 43,000 employees, nearly two-thirds of whom work in 51 manufacturing facilities located in 18 countries. Every day, over 5,500 Covidien sales representatives meet the needs of our customers in 70 countries. In all, our Company derives 45% of its sales from outside the United States. Covidien, formerly Tyco Healthcare, is a medical equipment and supply company, incorporated in Dublin, Ireland, although its corporate offices are located in Mansfield, Massachusetts, USA. On June 29, 2007, Covidien became an independent publicly traded company after being spun off from Tyco International.

Greenstone

Greenstone is a Peapack, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Context Therapeutics

Context Therapeutics Inc. (Nasdaq: CNTX) is a women`s oncology company developing advanced small molecule and immunotherapy treatments to transform care for hormone-driven breast and gynecological cancers. The Company`s robust clinical program for lead candidate onapristone extended release (ONA-XR) comprises three Phase 2 clinical trials and one Phase 1b/2 clinical trial in hormone-driven breast, ovarian and endometrial cancer, as well as two Phase 0 biomarker pharmacodynamic trials in breast cancer. ONA-XR is a novel small molecule under development as a complete antagonist of the progesterone receptor, a key unchecked mechanism in hormone-driven women`s cancers.